Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Carbone says Checkmate 227 used dual immunotherapy without chemotherapy and had almost exactly the same efficacy, including in PD-L1-negative subsets. He questions whether adding chemotherapy, especially four cycles, adds much benefit, and he notes that patients in his experience often like having only two cycles.

Related Insights

Multiple trials, including PACIFIC-2, have shown no survival benefit from adding immunotherapy concurrently with chemoradiation for unresectable Stage III NSCLC. This suggests that concurrent radiation may disrupt the immune-activating pathways necessary for immunotherapy to work, a critical lesson for future trial designs.

Real-world data suggests that using one antibody-drug conjugate (ADC) immediately after another is often ineffective. A potential strategy to overcome this resistance is to administer a different class of chemotherapy before starting the second ADC.

Data from the Podium-303 trial's crossover arm suggests that waiting to use a PD-1 inhibitor after progression on chemotherapy is less effective than using it concurrently from the start. This supports the synergistic effect of chemo-immunotherapy and favors the concurrent approach as the standard of care.

The rationale for combining ADCs with checkpoint inhibitors extends beyond additive effects. Preclinical data shows ADCs can increase T-cell infiltration into the tumor, potentially turning immunologically 'cold' tumors 'hot.' This offers a promising synergistic strategy, especially for PD-L1 negative patients who typically don't respond to immunotherapy alone.

The CheckMate 9LA regimen provides exceptional benefit to PD-L1 negative and squamous histology NSCLC patients. This is significant because these subgroups often respond poorly to other immunotherapy combinations, with Dr. Carbone noting some trials where the control arm outperformed pembrolizumab in these patients.

Carbone points to Keynote 407 five-year data where PD-L1-negative squamous tumors did so poorly that more control-arm patients were alive than treated patients. In his practice, he uses the 9LA dual immunotherapy regimen in that setting for those patients because long-term survival with chemoimmunotherapy is unimpressive.

KEYNOTE-522 data shows that achieving pathologic complete response (path CR) with pembrolizumab offers a greater survival benefit than achieving path CR with chemotherapy alone. This suggests immunotherapy provides a lasting benefit beyond just initial tumor eradication.

The ATTRACTION-6 trial surprisingly found that adding combination immunotherapy (ipilimumab + nivolumab) to first-line chemotherapy did not improve overall survival over chemotherapy alone in metastatic gastric cancer. This negative result reinforces that adding a single-agent checkpoint inhibitor to chemotherapy remains the global standard of care.

The next frontier in CSCC isn't just about new drugs, but about optimizing existing ones. A key research area is determining the minimum number of immunotherapy doses required for an optimal response—potentially just one or two—to limit toxicity, reduce treatment burden, and personalize care for high-risk patients.

Carbone says trial patients are fit, but real-world frailty or renal problems may favor less chemotherapy. He does not use age alone to withhold dual immunotherapy from patients over 80 with good performance and organ function, though interstitial lung disease or aggressive autoimmune disease may make dual immunotherapy a poor fit.